• Sangamo Therapeutics filed an amended Chapter 11 operating report on October 23, 2026, reporting an $11.17 million July net loss.
• Month-end cash totaled $16.91 million, compared with $14.38 million at the start of July.
• July borrowing under the Replacement DIP Facility totaled $18 million; $11.43 million satisfied outstanding Initial DIP Facility obligations, including fees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-434171), on October 27, 2026, and is solely responsible for the information contained therein.